Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial

Further Publications Urology

Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials

Prostate Cancer Prostatic Dis

Jiang T, Markovic D, Patel J, Juarez JE, Ma TM, Shabsovich D, Nickols NG, Reiter RE, Elashoff D, Rettig MB, Zaorsky NG, Spratt DE, Kishan AU

doi: 10.1038/s41391-021-00432-2

Uro-Oncology

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921

J Clin Oncol.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W1, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM

doi: 10.1200/JCO.2017.76.4126.

Uro-Oncology

Androgen deprivation therapy for prostate cancer and risk of dementia

BJU Int.

Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J

doi: 10.1111/bju.14666.

Uro-Oncology

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Eur Urol.

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, Leskinent MJ, Zeke M, Huttunen T, Ginman C, Investigators of the Scandinavian Prostate Cancer Study No. 13.

doi: 10.1016/j.eururo.2019.08.010.

Uro-Oncology

Risk of dementia following androgen deprivation therapy for treatment of prostate cancer

Prostate Cancer Prostatic Dis.

Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Mucci LA, Sun M, Trinh QD

doi: 10.1038/s41391-019-0189-3.

Further Publications Urology

Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer

J Urol

McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, Calagua C, Rathkopf D, Laudone VP, Bubley GJ, Einstein DJ, Chang PK, Wagner AA, Parsons JK, Preston MA, Kilbridge K, Chang SL, Choudhury AD, Pomerantz MM, Trinh QD, Kibel AS, Taplin ME

doi: 10.1097/JU.0000000000001702

Uro-Oncology

Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis

Prostate Cancer Prostatic Dis

Ussing A, Mikkelsen MK, Villumsen BR, Wejlgaard J, Bistrup PE, Birkefoss K, Bandholm T

doi: 10.1038/s41391-021-00450-0

Uro-Oncology

Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer

Cancer.

Jang TL, Patel N, Faiena I, Radadia KD, Moore DF, Elsamra SE, Singer EA, Stein MN, Eastham JA, Scardino PT, Lin Y, Kim IY, Lu-Yao GL

doi: 10.1002/cncr.31726.

Uro-Oncology

Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: modifying effects of exercise from a year-long randomized controlled trial

Prostate Cancer Prostatic Dis

Galvão DA, Newton RU, Chambers SK, Spry N, Joseph D, Gardiner RA, Fairman CM, Taaffe DR

doi: 10.1038/s41391-021-00327-2

Related content

Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921

Androgen deprivation therapy for prostate cancer and risk of dementia

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Risk of dementia following androgen deprivation therapy for treatment of prostate cancer

Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer

Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis

Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer

Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: modifying effects of exercise from a year-long randomized controlled trial